Provided by Tiger Trade Technology Pte. Ltd.

Turning Point Therapeutics

76.01
0.0000
Volume:- -
Turnover:216.02M
Market Cap:3.81B
PE:-11.01
High:76.01
Open:76.01
Low:76.01
Close:76.01
52wk High:82.20
52wk Low:23.77
Shares:50.07M
Float Shares:44.50M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.9067
EPS(LYR):-4.8016
ROE:-36.80%
ROA:-22.13%
PB:4.80
PE(LYR):-15.83

Loading ...

Company Profile

Company Name:
Turning Point Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.